Quantum dots: An insight and perspective of their biological interaction and how this relates to their relevance for clinical use

Theranostics

Volumn 2, Issue 7, 2012, Pages 668-680

  Clift, Martin J D ^a   Stone, Vicki ^b  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

Clinical relevance; Human health effects; Nanocrystals; Nanomedicine; Nanoparticles; NP cell interactions; Quantum dots

Indexed keywords

GOLD NANOPARTICLE; NANOCRYSTAL; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ARTICLE; CHEMICAL COMPOSITION; ENDOSOME; HUMAN; LIGHT; LYSOSOME; NONHUMAN; PHYSICAL CHEMISTRY; SEMICONDUCTOR;

EID: 84866044936     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4545     Document Type: Article

References (93)

1. ISO. International Organization for Standardization (ISO) Technical Specification (ISO/TS) 27687:2008; Nanotechnologies - Terminology and definitions for nano-objects - Nanoparticle, nanofibre and nanoplate; First published 2008-08-15. ISO. 2008.
2. Pison U, Welte T, Giersig M, Groneberg D.A. Nanomedicine for respir-atory diseases. Eur J Pharm. 2006; 533: 341-350.
3. Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A. As-sessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem Rev. 2012; 112: 2323-2338.
4. Hardman R. A toxicologic review of quantum dots: Toxicity depends on physiochemical and environmental factors. Environ Health Perspec. 2006; 114: 165-172.
5. Azzazy H.M.E, Mansour M.M.H, Kazmierczak S.C. From diagnostics to therapy: Prospects of quantum dots. Clin Biochem. 2007; 40: 917-927.
6. Pelly JL, Daar AS, Saner MA. State of academic knowledge on toxicity and biological fate of quantum dots. Toxicol Sci. 2009; 112: 276-296.
7. Maynard A.D. Nanotechnology: The next big thing, or much ado about nothing? Ann Occu Hyg.2007; 51: 1-12.
8. Müller L, Gasser M, Raemy D.O, Herzog F, Brandenberger C, Schmid O, Gehr P, Rothen-Rutishauser B, Clift M.J.D. Realistic exposure methods for investigating the interaction of nanoparticles with the lung at the air-liquid interface in vitro. InSci J (Nanotech). 2011; 1: 30-64.
9. Kreyling W.G, Hirn S, Schleh C. Nanoparticles in the lung. Nat Biotech. 2010; 28: 1275-1276.
10. Johnston H.J, Semmler-Behnke M, Brown D.M, Kreyling W, Tran L, Stone V. Evaluating the uptake and intracellular fate of polystyrene na-noparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharm. 2010; 242: 66-78.
11. Geys J, De Vos R, Nemery B, Hoet P.H.M. In vitro translocation of quantum dots and influence of oxidative stress. Am J Physiol Lung Cell Mol Physiol. 2009; 297: L903-L911.
12. Oberdorster G, Stone V, Donaldson K. Toxicology of nanoparticles: A historical perspective. Nanotox. 2007; 1: 2-25.
13. Ryman-Rasmussen J.P, Riviere J.E, Monteiro-Riviere N.A. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci. 2006; 91: 159-165.
14. Ryman-Rasmussen J.P, Riviere J.E, Monteiro-Riviere N.A. Surface coat-ings determine cytotoxicity and irritation potential of quantum dot na-noparticles in epidermal kerationcytes. J Inves Derm. 2006; 127: 143-153.
15. Ryman-Rasmussen J.P, Riviere J.E, Monteiro-Riviere N.A. Variables influence interactions of untargeted quantum dot nanoparticles with skin cells an indentification of biochemical modulators. Nano Letts. 2007; 7: 1344-1348.
16. Wiesner M.R, Lowry G.V, Alvarez P, Dionysiou D, Biswas P. Assessing the risks of manufactured nanomaterials. Environ Sci Technol. 2006; 15: 4337-4345.
17. Summers H.D, Holton M.D, Rees P, Williams P.M, Thornton C.A. Anal-ysis of quantum dot fluorescence stability in primary blood mononuclear cells. Cytom A. 2010; 77A: 933-939.
18. Rothen-Rutishauser B.M, Schuerch S, Haenni B, Kapp N, Gehr P. Inter-action of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol. 2006; 40: 4353-4359.
19. Alves E.N, Presgravede R.F, Presgrave O.A, Sabagh FP, de Freitas JC, Corrado A.P. A reassessment of the in vitro RBC haemolysis assay with defibrinated sheep blood for the determination of the ocular irritation potential of cosmetic products: comparison with the in vivo Draize rab-bit test. Altern Lab Anim.2008; 36: 275-284.
20. Li X, Wang L, Fan Y, Feng Q, Cui F-Z. Biocompatibility and toxicity of nanoparticles and nanotubes. J Nanomat. 2012; doi:10.1155/2012/548389.
21. Lu S, Duffin R, Poland C, Daly P, Murphy F, Drost E, MacNee W, Stone V, Donaldson K. Efficacy of simple short-term in vitro assays for pre-dicting the potential of metal oxide nanoparticles to cause pulmonary inflammation. Environ Health Perspec. 2009; 117: 241-247.
22. Zhu O, Wang Y, Zhou M, Mao C, Huang X, Bao J, Shen J. Preparation of anionic polyurethane nanoparticles and blood compatible behaviors. J Nanosci Nanotech. 2012; 12: 4051-4056.
23. Huang Z.W, Ding TT, Sun J. Study of Effect on Cell proliferation and Hemolysis of HAP and TCP Nanometer Particles. Adv Mater Res. 2011; 711: 378-379.
24. Shen M, Cai H, Wang X, Cao X, Li K, Wang SH, Guo R, Zheng L, Zhang G, Shi X. Facile one-pot preparation, surface functionalization, and tox-icity assay of APTS-coated iron oxide nanoparticles. Nanotech. 2012; 23: 105601.
25. Su,Y, Peng F, Jiang Z, Zhong Y, Lu Y, Jiang X, Huang Q, Fan C, Lee, S-T, He Y. In vivo distribution, pharmacokinetics, and toxicity of aqueous synthesized cadmium-containing quantum dots. Biomaterials. 2011; 32: 5855-5862.
26. Bailey R.E, Smith A.M, Nie S. Quantum dots in biology and medicine. Physica E. 2004; 25: 1-12.
27. Derfus A.M, Chan W.C.W, Bhatia S.N. Probing the cytotoxicity of semi-conductor quantum dots. Nano Letts. 2004; 4: 11-18.
28. Walling MA, Novak JA, Shepard JRE. Quantum dots for live cell and in vivo imaging. Int J Mol Sci. 2009; 10: 441-491.
29. Tilley RD. Synthesis and applications of nanoparticles and quantum dots. Chem NZ. 2008; :146-150.
30. O'Farrell N, Houlton A, Horrocks BR. Silicon nanoparticles: applications in cell biology and medicine. Int J Nanomed. 2006; 1: 451-472.
31. Ferin J, Oberdorster G, Penney D.P. Pulmonary retention of ultrafine and fine particles in rats. Am J Respir Cell Mol Biol. 1992; 6: 535-542.
32. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspec. 2005; 113: 823-839.
33. Duffin R, Tran L, Brown D, Stone V, Donaldson K. Proinflammogenic effects of low-toxicity and metal nanoparticles in vivo and in vitro: Highlighting the role of particle surface area and surface reactivity. Inhal Toxicol. 2007; 19: 849-856.
34. Bouwmeester H, Lynch I, Marvin H.J.P, Dawson K.A, Berges M, Braguer D, Byrne H.J, Casey A, Chambers G, Clift M.J.D, Elia G, Fernandes T.F, Fjellsbø L.B, Hatto P, Juillerat L, Klein C, Kreyling W.G, Nickel C, Riediker M, Stone V. Minimal analytical characterisation of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotox. 2011; 5: 1-11.
35. Nel A.E, Maedler L, Velegol D, Xia T, Hoek E.M.V, Somasundaran P, Klaessig F, Castranova V, Thompson M. Understanding biophysico-chemical interactions at the nano-bio interaface. Nat Mater. 2009; 8: 543-557.
36. Lynch I, Dawson K.A. Protein-nanoparticle interactions. Nanotoday. 2008; 3: 40-47.
37. Monopoli M.P, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli F.B, Dawson K.A. Physical-Chemical aspects of protein corona: Relevance to in vitro and in vivo biological impacts of nanoparticles. JACS. 2011; 133: 2525-2534.
38. Wick P, Manser P, Limbach L.K, Dettlaff-Weglikowska U, Krumeich F, Roth S, Stark W.J, Bruinink A. The degree and kind of agglomeration affect carbon nanotube cytotoxicity. Tox Letts. 2007; 168: 121-131.
39. Duncan R. The dawning era of polymer therapeutics. Nat Drug Discov. 2003; 2: 347-360.
40. Moghimi S.M, Szebeni J. Stealth liposomes and long circulating nano-particles: critical issues in pharmacokinetics, opsonization and pro-tein-binding properties. Pro Lipid Res. 2003; 42: 463-478.
41. Moghimi SM. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Bio-materials. 2006; 27: 136 - 144.
42. Porter C.J.H, Moghimi S.M, Illum L, Davis S.S. The polyoxyeth-ylene/polyoxyproplylene block co-polymer Poloxamer-407 selectiely redirects intravenously injected microspheres to sinusoidal dothelial cells of rabbit bone marrow. FEBS Letts. 1992; 305: 62-66.
43. Gref R, Minamitake Y, Peracchia M.T, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994; 263: 1600-1603.
44. Storm G, Belliot S.O, Daemen T, Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Del Rev. 1995; 17: 31-48.
45. Peracchia M.T, Fattal E, Desmaele D, Besnard M, Noel J.P, Gomis J.M. Stealth PEGylated polycyanoacrylate nanoparticles. Eur J Pharm Bio-pharm. 1999; 58: 327-341.
46. Hayes M.E, Drummond D.C, Hong K, Zheng W.W, Khorosheva V.A, Cohen J.A, Noble IV C.O, Park J.W, Marks J.D, Benz C.C, Kirpotin D.B. Increased target specificity of Anti-HER2 genospheres by modification of surface charge and degree of PEGlyation. Mol Pharm. 2006; 3: 726-736.
47. Veronese F.M, Pasut G. PEGylation, successful approach to drug deliv-ery. Drug Discovery Today. 2005; 10: 1451-1458.
48. Zhang T, Stilwell J.L, Gerion D, Ding L, Elboudwarej O, Cooke P.A, Gray J.W, Alivisatos A.P, Chen F.F. Cellular effect of high doses of sili-ca-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Letts. 2006; 6: 800-808.
49. Duan H, Nie S. Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. JACS. 2007; 129: 3333-3338.
50. Clift M.J.D, Rothen-Rutishauser B, Brown D.M, Duffin R, Donaldson K, Proudfoot L, Guy K, Stone V. The Impact of Different Nanoparticle Sur-face Chemistry and Size on Uptake and Toxicity in a Murine Macro-phage Cell Line. Toxicol Appl Pharm. 2008; 232: 418-427.
51. Clift M.J.D, Varet J, Hankin S.M, Brownlee B, Davidson A, Branden-berger C, Rothen-Rutishauser B, Brown D.M, Stone V. Quantum dot cy-totoxicity in vitro: An investigation into the cytotoxic effects of a series of different surface chemistries and their core/shell materials. Nanotox. 2011; 5: 664-674.
52. Clift M.J.D, Boyles M.S.P, Brown D.M, Stone V. An investigation into the potential for different surface coated quantum dots to cause oxidative stress and affect macrophage cell signalling in vitro. Nanotox. 2010; 4: 139-149.
53. World Health Organisation. International Programme on Chemical Safety; Environmental Health Criteria (EHC) 134; Cadmium. WHO. 1992
54. Stohs S.J, Bagchi D. Oxidative mechanisms in the toxicity of Metal Ions. Free Rad Biol Med. 1995; 18: 321-336.
55. Belyaeva E.A, Korotkov S.M. Mechanism of primary Cd2+ -induced rat liver mitochondria dysfunction: discrete modes of Cd2+ action on cal-cium and thiol-dependent domains. Toxicol Appl Pharm. 2003; 192: 56-68.
56. Stohs S.J, Bagchi D, Hassoun E, Bagchi M. Oxidative mechanisms in the toxicity of chromium and cadmium ions. J Environ Path Toxicol Oncol. 2001; 20: 77-88.
57. Sadler P.J, Viles J.H. 1H and 113C NMR Investigations of Cd2+ and Zn2+ Binding Sites on Serum Albumin: Competition with Ca2+, Ni2+, Cu2+, and Zn2+. Inorg Chem. 1996; 35: 4490-4496.
58. Shiohara A, Hoshino A, Hanaki K, Suzuki K, Yamamoto K. On the cyto-toxicity caused by quantum dots. Microbiol Immunol. 2004; 48: 669-675.
59. Hoshino A, Fujioka K, Oku T, Masakazu S, Sasaki Y.F, Ohta T, Yasuhara M, Suzuki K, Yamamoto K. Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modifica-tion. Nano Letts. 2004; 4: 2163-2169.
60. Hoshino A, Hanaki K, Suzuki K, Yamamoto K. Applications of T-lymphoma labelled with fluorescent quantum dots to cell tracing markers in mouse body. Biochem Biophys Res Comm. 2004; 314: 46-53.
61. Chan W, Shiao N, Lu P. CdSe quantum dots induce apoptosis in human neuroblastoma cells via mitochondrial-dependent pathways and inhibi-tion of survival signals. Tox Letts. 2006; 167: 191-200.
62. Guo G, Liu W, Liang J, He Z, Xu H, Yang X. Probing the cytotoxicity of CdSe quantum dots with surface modification. Mater Lett. 2007; 61:1641-1644.
63. Lovric J, Bazzi H.S, Cuie Y, Fortin G.R.A, Winnik F.M, Maysinger D. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med. 2005; 83: 377-385.
64. Geys J, Nemmar A, Verbeken E, Smolders E, Ratoi M, Hoylaerts MF, Nemery B, Hoet PHM. Acute toxicity and prothrombotic effects of quantum dots: Impact of surface charge. Environ Health Perspec. 2008; 116: 1607-1613.
65. Hoshino A, Hanada S, Yamamoto K. Toxicity of nanocrystal quantum dots: the relevance of surface modifications. Arch Toxicol. 2011; 85: 707-720.
66. Clift M.J.D, Brandenberger C, Rothen-Rutishauser B, Brown D.M, Stone V. The uptake and intracellular fate of a series of different surface coated quantum dots in vitro. Toxicol. 2011; 286: 58-68.
67. Lovric J, Cho S.J, Winnik F.M, Maysinger D. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol. 2005; 12: 1-8.
68. Clift M.J.D, Gehr P. Rothen-Rutishauser B. In vitro Testing for Nanotox-icology: A valid alternative? Arch Toxicol. 2011; 85: 723-731.
69. Maysinger D, Lovric J, Eisenberg A, Savic R. Fate of micelles and quan-tum dots in cells. Eur J Pharm Biopharm.2007; 65:270-281.
70. Zhang L.W, Monteiro-Riviere N.A. Mechanisms of quantum dot nano-particle cellular uptake. Toxicol Sci. 2009; 110: 138-155.
71. Jaiswal J.K, Mattoussi H, Mauro J.M, Simon S.M. Long-term multiple colour imaging of live cells using quantum dot bioconjugates. Nat Bio-tech. 2003; 21: 47-51.
72. Dubertret B, Skourides P, Norris D.J, Noireaux V, Brivanlou A.H, Lib-chaber A. In vivo imaging quantum dots encapsulated in phospholipids micelles. Sci. 2002; 289: 1759-1762.
73. Larson D.R, Zipfel W.R, Williams R.M, Clark S.W, Bruchez M.P, Wise F.W. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Sci. 2003; 300: 1434-1436.
74. Xu L, Chen K, El-Khair H.M, Li M, Huang X. Enhancement of band-edge luminescence and photo-stability in colloidal CdSe quantum tods by various surface passivation technologies. Appl Surf Sci. 2001; 172: 84-88.
75. Mout R, Moyano DF, Rana S, Rotello VM. Suface functionalization of nanoparticles for nanomedicine. Chem Soc Rev. 2012; 41: 2539-2544.
76. Parak W.J, Boudreau R, LeGros M, Gerion D, Zanchet D, Micheel C.M. Cell motility and metastatic potential studies based on quantum dot imaging of phagokineitc tracks. Adv Mater. 2002; 14: 882-885.
77. Ness J.M, Akhtar R.S, Latham C.B, Roth K.A. Combined tyramide Signal amplification and quantum dots for sensitive and photostable immuno-fluorescence detection. J Histochem Cytochem. 2003; 51: 981-987.
78. Lidke D.S, Nagy P, Heintzmann R, Arndt-Jovin D.J, Post J.N, Grecco H.E, Jares-Erijman E.A, Jovin T.M. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Bi-otech. 2004; 22: 198-203.
79. Nisman R, Dellaire G, Ren Y, Li R, Bazett-Jones D.P. Application of quantum dots as probes of correlative fluorescence, conventional, and energy-filtered transmission electron microscopy. J Histochem Cyto-chem. 2004; 52: 13-18.
80. Gao X, Yang L, Petro J.A, Marshall F.F, Simons J.W, Nie S. In vivo mo-lecular and cellular imaging with quantum dots. Cur Opin Biotech. 2005; 16: 63-72.
81. Giepmans B.N.G, Deerinck T.J, Smarr B.L, Jones Y.Z, Ellisman M.H. Correlated light and electron microscopic imaging of multiple endoge-nous proteins using quantum dots. Nat Meth. 2005; 2: 743-749.
82. Kloepfer J.A, Mielke R.E, Nadeau J.L. Uptake of CdSe and CdSe/ZnS quantum dots into bacteria via purine-dependent mechanisms. Appl Environ Microbiol. 2005; 71: 2548-2557.
83. Mason J.N, Farmer H, Tomlinson I.D, Schwartz J.W, Savchenko V, De-Felice L.J, Rosenthal S.J, Blakely R.D. Novel fluorescence based ap-proaches for the study of biogenic amine transporter localization, activ-ity and regulation. J Neurosci Meth. 2005; 143: 3-25.
84. Pinaud F, Michalet X, Bentolila L.A, Tsay J.M, Doose S, Li J.J, Iyer G, Weiss S. Advances in fluorescence imaging with quantum dot bio-probes. Biomaterials. 2006; 27: 1679-1687.
85. Michalet X, Pinaud F.F, Bentolila L.A, Tsay J.M, Doose S, Li J.J, Sundaresan G, Wu A.M, Gambhir S.S, Weiss S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005; 307: 538-544.
86. Gao X, Cui Y, Levenson R.M, Chung L.W.K, Nie S. In vivo cancer tar-geting and imaging with semiconductor quantum dots. Nat Biotech. 2004; 22: 969-976.
87. Wu X, Liu H, Liu J, Haley K.N, Treadway J.A, Larson J.P, Ge N, Peale F, Bruchez M.P. Immunofluorescent labelling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotech. 2003; 21: 41-46.
88. Kim S, Lim Y.T, Soltesz E.G, De Grand A.M, Lee J, Nakayama A, Parker J.A, Mihalejevic T, Laurence R.G, Dor D.M, Chon O.L.H, Bawedni M.G, Frangioni J.V. Near-infrared fluorescent type II quantum dots for senti-nel lymph node mapping. Nat Biotech. 2004; 22: 93-97.
89. Gao J, Chen K, Luong R, et al. A novel clinically translatable flurescent nanoparticle for targeted molecular imaging of tumors in living subjects. Nano Letts. 2012; 12: 281-286.
90. Oberdorster G. Safety assessment for nanotechnology and nanomedi-cine: concepts of nanotoxicology. J Int Med. 2010; 267: 89-105.
91. Ye L, Yong K-T, Liu L, et al. A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat Nanotech. 2012; DOI: 10.1038/NNANO.2012.74
92. Ghaderi S, Ramesh B, Seifalian AM. Fluorescence nanoparticles " quan-tum dots" as drug delivery system and their toxicity: a review. J Drug Target. 2011; 19: 475-486.
93. Rothen-Rutishauser B, Blank F, Muehlfeld C, Gehr P. In vitro models of the human epithelial airway barrier to study the toxic potential of par-ticulate matter. Exp Opin Drug Metab Toxicol. 2008; 4: 1075-1089.